Company Overview: Inovio

Industry News

29 Nov

Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

PLYMOUTH MEETING, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success.  VGX-3100, Inovio’s lead product now in a pivotal phase 3 trial,...

Read more

27 Nov

Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model

PLYMOUTH MEETING, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical tumor model. The combination therapies resulted in robust anti-tumor effects and showed significant improvement in...

Read more

10 Nov

Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference

PLYMOUTH MEETING, Pa., Nov. 10, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that two of its cancer immunotherapies demonstrated antigen-specific T-cell stimulation in phase 1 studies. INO-3112 (now called MEDI0457), an investigational T-cell activation immunotherapy that targets cancers caused by human papillomavirus (HPV) types 16 and...

Read more

9 Nov

Inovio Pharmaceuticals to Participate In Upcoming Investment Conferences

PLYMOUTH MEETING, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that the Company will participate in the following upcoming investment conferences: Stifel 2017 Healthcare Conference Presentation and 1×1 meetings Dr. Niranjan Y. Sardesai, COO 11:45 AM ET, November 15, 2017 New York, NY 29th Annual...

Read more

1 Nov

Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor

PLYMOUTH MEETING, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today initiated a phase 1b/2a immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) designed to evaluate cemiplimab (also known as REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals, Inc. (REGN), in combination with Inovio’s INO-5401...

Read more

Page 1 of 1412345...10...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address